Avidex and ChemOvation extend collaboration

Published: 28-Jan-2004

Biotechnology company Avidex and drug discovery service provider ChemOvation have signed an agreement to extend their successful 2003 small molecule programme for Rhudex, Avidex's CD80 inhibitor for rheumatoid arthritis (RA).


Biotechnology company Avidex and drug discovery service provider ChemOvation have signed an agreement to extend their successful 2003 small molecule programme for Rhudex, Avidex's CD80 inhibitor for rheumatoid arthritis (RA).

Under the terms of the agreement, full details of which have not been disclosed, ChemOvation will be providing Avidex with medicinal chemistry services and expertise for selection of a follow-on lead candidate in this therapeutic approach.

'The Rhudex product development programme is advancing in a structured and ordered way to the clinic,' said Dr David McGibney, development director at Avidex. 'Our leads have nanomolar binding affinities and show oral bioavailability above the cellular IC50 for inhibition of cytokine release from T cells.'

  

You may also like